一米八八
Lv63
2400 积分
2023-06-12 加入
-
胰高糖素样肽‐1 受体激动剂类药物结合生活方式干预减重专家共识(2024 版)
1个月前
已完结
-
NEJM at ESC — Asundexian versus Apixaban in Patients with Atrial Fibrillation
2个月前
已关闭
-
Asundexian versus Apixaban in Patients with Atrial Fibrillation
2个月前
已完结
-
肥胖患者的长期体重管理及药物临床应用指南(2024版)
3个月前
已完结
-
Changes in Gastric Inhibitory Polypeptide (GIP) After Roux-en-Y Gastric Bypass in Obese Patients: a Meta-analysis
4个月前
已完结
-
Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study
5个月前
已完结
-
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
7个月前
已完结
-
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
8个月前
已完结
-
Once-Weekly Semaglutide in Adults with Overweight or Obesity
8个月前
已关闭
-
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
8个月前
已关闭